459 related articles for article (PubMed ID: 26657538)
1. Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?
Moya-Alvarado G; Gershoni-Emek N; Perlson E; Bronfman FC
Mol Cell Proteomics; 2016 Feb; 15(2):409-25. PubMed ID: 26657538
[TBL] [Abstract][Full Text] [Related]
2. OCIAD1 contributes to neurodegeneration in Alzheimer's disease by inducing mitochondria dysfunction, neuronal vulnerability and synaptic damages.
Li X; Wang L; Cykowski M; He T; Liu T; Chakranarayan J; Rivera A; Zhao H; Powell S; Xia W; Wong STC
EBioMedicine; 2020 Jan; 51():102569. PubMed ID: 31931285
[TBL] [Abstract][Full Text] [Related]
3. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain.
Butterfield DA; Di Domenico F; Swomley AM; Head E; Perluigi M
Biochem J; 2014 Oct; 463(2):177-89. PubMed ID: 25242166
[TBL] [Abstract][Full Text] [Related]
4. Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration.
Cortes-Canteli M; Mattei L; Richards AT; Norris EH; Strickland S
Neurobiol Aging; 2015 Feb; 36(2):608-17. PubMed ID: 25475538
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease and amyloid: culprit or coincidence?
Skaper SD
Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
[TBL] [Abstract][Full Text] [Related]
6. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases.
Mattson MP; Pedersen WA; Duan W; Culmsee C; Camandola S
Ann N Y Acad Sci; 1999; 893():154-75. PubMed ID: 10672236
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analysis of oxidatively modified proteins in Alzheimer's disease brain: insights into neurodegeneration.
Butterfield DA; Castegna A
Cell Mol Biol (Noisy-le-grand); 2003 Jul; 49(5):747-51. PubMed ID: 14528911
[TBL] [Abstract][Full Text] [Related]
8. Comparative profiling of the synaptic proteome from Alzheimer's disease patients with focus on the APOE genotype.
Hesse R; Hurtado ML; Jackson RJ; Eaton SL; Herrmann AG; Colom-Cadena M; Tzioras M; King D; Rose J; Tulloch J; McKenzie CA; Smith C; Henstridge CM; Lamont D; Wishart TM; Spires-Jones TL
Acta Neuropathol Commun; 2019 Dec; 7(1):214. PubMed ID: 31862015
[TBL] [Abstract][Full Text] [Related]
9. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease.
Bader JM; Geyer PE; Müller JB; Strauss MT; Koch M; Leypoldt F; Koertvelyessy P; Bittner D; Schipke CG; Incesoy EI; Peters O; Deigendesch N; Simons M; Jensen MK; Zetterberg H; Mann M
Mol Syst Biol; 2020 Jun; 16(6):e9356. PubMed ID: 32485097
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in Sporadic and Familial Alzheimer's Disease.
Lista S; O'Bryant SE; Blennow K; Dubois B; Hugon J; Zetterberg H; Hampel H
J Alzheimers Dis; 2015; 47(2):291-317. PubMed ID: 26401553
[TBL] [Abstract][Full Text] [Related]
11. Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy.
Wu T; Dejanovic B; Gandham VD; Gogineni A; Edmonds R; Schauer S; Srinivasan K; Huntley MA; Wang Y; Wang TM; Hedehus M; Barck KH; Stark M; Ngu H; Foreman O; Meilandt WJ; Elstrott J; Chang MC; Hansen DV; Carano RAD; Sheng M; Hanson JE
Cell Rep; 2019 Aug; 28(8):2111-2123.e6. PubMed ID: 31433986
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease.
Wirths O; Breyhan H; Marcello A; Cotel MC; Brück W; Bayer TA
Neurobiol Aging; 2010 May; 31(5):747-57. PubMed ID: 18657882
[TBL] [Abstract][Full Text] [Related]
13. Using proteomics and network analysis to elucidate the consequences of synaptic protein oxidation in a PS1 + AbetaPP mouse model of Alzheimer's disease.
Soreghan BA; Lu BW; Thomas SN; Duff K; Rakhmatulin EA; Nikolskaya T; Chen T; Yang AJ
J Alzheimers Dis; 2005 Dec; 8(3):227-41. PubMed ID: 16340081
[TBL] [Abstract][Full Text] [Related]
14. Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease.
Nixon RA; Cataldo AM
J Alzheimers Dis; 2006; 9(3 Suppl):277-89. PubMed ID: 16914867
[TBL] [Abstract][Full Text] [Related]
15. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
16. A dual mechanism linking NGF/proNGF imbalance and early inflammation to Alzheimer's disease neurodegeneration in the AD11 anti-NGF mouse model.
Capsoni S; Brandi R; Arisi I; D'Onofrio M; Cattaneo A
CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):635-47. PubMed ID: 21631402
[TBL] [Abstract][Full Text] [Related]
17. Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.
Perluigi M; Di Domenico F; Buttterfield DA
Proteomics Clin Appl; 2014 Feb; 8(1-2):73-85. PubMed ID: 24259517
[TBL] [Abstract][Full Text] [Related]
18. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain.
Butterfield DA
Brain Res; 2004 Mar; 1000(1-2):1-7. PubMed ID: 15053946
[TBL] [Abstract][Full Text] [Related]
19. Inflammation, neurodegeneration and protein aggregation in the retina as ocular biomarkers for Alzheimer's disease in the 3xTg-AD mouse model.
Grimaldi A; Brighi C; Peruzzi G; Ragozzino D; Bonanni V; Limatola C; Ruocco G; Di Angelantonio S
Cell Death Dis; 2018 Jun; 9(6):685. PubMed ID: 29880901
[TBL] [Abstract][Full Text] [Related]
20. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P
J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
